Harper Molly 4

What Happened

• Molly Harper, a director of Catalyst Pharmaceuticals, disposed of a total of 130,857 shares or share-equivalents on July 15, 2026 in connection with the company’s acquisition by Angelini Pharma S.p.A. The filing shows 3,694 common shares sold to the issuer at $31.50 per share for $116,361. The remaining reported items were derivative awards (stock options and restricted stock units) that were cancelled and converted into cash as part of the merger.

Key Details

• Transaction date: 2026-07-15 (reported on Form 4 filed 2026-07-17). Transaction code: D (Disposition to issuer).
• Price(s): $31.50 per share for the 3,694 common shares (other derivative lines show $0 on the form but, per footnotes, were converted to cash under the merger terms).
• Total reported disposed: 130,857 shares/equivalents (3,694 common shares + 127,163 options/RSUs).
• Shares owned after the transaction: not disclosed in the data provided.
• Important footnotes from the filing:
  • F1: Dispositions occurred in connection with the consummation of the Angelini merger.
  • F2: RSUs represented contingent rights to receive one share each.
  • F3/F4: Each option and RSU was cancelled and converted into a cash payment based on the $31.50 merger price (options paid the excess over the option strike; RSUs paid $31.50 per share), less tax withholdings.
  • F5/F6: The reported options and RSUs were fully vested (vested in full upon consummation of the merger).
• Filing timeliness: Form 4 was filed two days after the transaction date (appears timely under standard Form 4 rules).

Context

• These were not open-market sales but disposals to the issuer and cash settlements tied to a change-of-control transaction. Derivative awards (options and RSUs) were cancelled and converted into cash per the merger agreement; options had already vested. Such transactions are common when a company is acquired and generally reflect merger consideration rather than a director’s directional view on the stock.